Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Stock Information for Greenwich LifeSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Greenwich LifeSciences Inc.

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.